Andrew Cheng, President and CEO at Akero Therapeutics, Inc. (AKRO), sold 49,873 shares at $49.77 ($2.5M) on 2023-09-01, disclosed to the SEC on 2023-09-18.
Scheduled sale ($2.5M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.77 | 24,873 | $1.2M | 49.9% |
| 2 | $49.77 | 24,873 | $1.2M | 49.9% |
| 3 | $50.24 | 127 | $6K | 0.3% |
| Total | $49.77 avg | 49,873 | $2.5M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-13 | $2.9M | — | Filing → |
| AKRO | SELL | 2025-07-11 | $3.1M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $726K | — | Filing → |